Partner With Us NRI

Company details

6M Return -2.66%
1Y Return 37.65%
Mkt Cap.(Cr) 788.28
Volume 1,527,097
Div Yield 0.00%
OI Chg %
Volume 1,527,097

Open Free Demat Account Online with ICICIDIRECT


  • swot

  • technicals

  • deals

  • shareholding


Delivery and volume


  • Profit and loss statement

  • Balance sheet

  • Quarterly Result

  • Ratio


Operating Profit(Cr.)

Profit after Tax(Cr.)


Reserves and Surplus



Operating Profit

Profit after tax





Equity Capital: 177.84 Cr FV: 1.00
Period MF Net Purchase / (sold) FII Net
LAST 1M 23,806.36 -39,994.59
LAST 3M 79,235.45 -52,306.79
LAST 6M 143,739.24 -201,556.99
LAST 12M 206,053.08 -176,593.86


  • About Company
  • Company Info
  • Listing Info
  • Incorporated as a private limited company in 1988, Syncom Formulations (India) was converted into a public limited company in Jun.`92. The company set up a manufacturing facility at Palghar, Thane to produce pharmaceutical formulations. Commercial production commenced in Apr.`89. Promoters are Kedarmal Bankda, Vijay Kumar Bankda and Ajay Kumar Bankda. In addition to pharmaceutical formulations in the form of tablets, capsules, liquids and dry powders, the company also manufactures injectibles and ear/eye drops on a loan licence basis. In 1994, the company undertook an expansion programme of setting up a new plant for manufacturing pharmaceutical formulations at Pithampur, Madhya Pradesh. The project which was financed through a public issue made in Jan.`94 was completed in 1995. During the year 1997-98, the Company has further diversified into Ethical Operations by introducing the range of prescription formulations. During the year 1998-99 there has been huge expansion of installed capacity and production base. Further the company plans introduction of products in the generic, OTC and Ethical Divisions. The export earnings have also registered a growth of more than 100%. During the year 1999-2000, the company and its associates have received export orders worth Rs.700.00 lacs against advance payment and hence better turnover is expected during the year. The company presently exports goods to Guine, Ghana, Kenya, Tanzania, Nigeria in Africa, Azberjan, Nepal and Srilanka in Asia. The company has been approved as a supplier to Central ESI Hospitals and registration of defence services is in its final stages, as a result of which will generate substantial sales volume. Keeping in view the shifting consumer preferenes for the use of herbal products, the company is aggressively manufacturing and marketing its herbal products like Edicare, Attom Megacaps, Ecziguard and Yas antacid salt.

Read More

Registered Address

7 Niraj Indl Estate Andheri(E), Off Mahakali Caves Rd, Mumbai, Maharashtra, 400093

Tel : 91-22-30887744
Email : info:sfil.in / finance:sfil.in
Website : http://www.sfil.in


Ankit Consultancy Pvt Ltd

AGM Date (Month) : Sep
Face Value Equity Shares : 1
Market Lot Equity Shares : 1
BSE Code : 524470
NSE Code :
Book Closure Date (Month) : Sep
BSE Group : X
ISIN : INE312C01025

ICICIdirect Syncom Formulations (India) Ltd FAQ

You can buy Syncom Formulations (India) Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Syncom Formulations (India) Ltd Share.
Company share prices and volatile and keep changing according to the market conditions. As of May 20, 2022 04:01 PM the closing price of Syncom Formulations (India) Ltd was ₹ 9.14.
Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of May 20, 2022 04:01 PM, the market cap of Syncom Formulations (India) Ltd stood at ₹ 788.28.
The latest PE ratio of Syncom Formulations (India) Ltd as of May 20, 2022 04:01 PM is 39.74
The latest PB ratio of Syncom Formulations (India) Ltd as of May 20, 2022 04:01 PM is 0.28
The 52-week high of Syncom Formulations (India) Ltd is ₹ 19.49 while the 52-week low is ₹ 5.76 .

Thank you for subscribing to Equity/ Equity Research/MF/FnO Newsletter. You will hear from us shortly.

for your vote